The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
October 2024 — Vol. 1, No. 10
Page 4 of 4 of this archive, newest first.
Also filed — page 4
the rolling newsroom, October 2024Japan pharmacy body issues counselling standards for exenatide initiation
The evidence base is thin and the document says so, which is to its credit.
CPC declines, for the 23rd time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
France declines to reimburse semaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Calder Vale Peptides of Skipton closes after 16 years
A proper account of an operation that existed, and of what closing it cost.
What the new Japan guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What changed at CPC in October, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Medutest result on a Xi'an semaglutide lot lands 3.3 points below the supplier’s figure
The supplier has not disputed the finding. It has not explained the gap either.
The relabeller trading as Vantris Bio enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
A supplier suspends shipping to Nigeria after 14 consecutive customs detentions
The route did not close because of a rule about peptides.
Halvard & Pike Apothecary of Portland, Maine enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
From the floor in Changsha: 21 posters, one theme
Reported from the sessions, and from the two hours afterwards.
The 13-day notice: how a compounding wind-down works in Argentina
The document is four pages. Three of them are about dates.
Inspectors cite Calder Vale Peptides of Skipton over sterility assurance
The observation that closes a facility is rarely the dramatic one.
Nigeria caps liraglutide prescribing to 21 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
LEADER extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
A shortage listing ends. 11 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The quiet end of the consolidator trading as Meridian Freight Partners
A proper account of an operation that existed, and of what closing it cost.
Independent analysis puts a TFC tirzepatide lot at 97.7%, against 95.0% on the certificate
The report states the gradient, the wavelength and the integration threshold, which is more than most.
SSA declines, for the 15th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.